Regeneron Pharmaceuticals

Regeneron Pharmaceuticals logo
🇺🇸United States
Ownership
Public
Established
1988-01-01
Employees
13.4K
Market Cap
$132.4B
Website
http://www.regeneron.com
Introduction

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...

Clinical Trials
Related News

Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares

Phase 3
Terminated
Conditions
Gout
Interventions
Drug: Placebo
Drug: Rilonacept
Drug: Allopurinol
First Posted Date
2011-10-26
Last Posted Date
2017-07-18
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
220
Registration Number
NCT01459796

Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol

First Posted Date
2011-10-14
Last Posted Date
2014-05-12
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
82
Registration Number
NCT01451645

Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis

First Posted Date
2011-06-30
Last Posted Date
2020-02-26
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
37
Registration Number
NCT01385657

Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema

First Posted Date
2011-06-01
Last Posted Date
2016-05-30
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
466
Registration Number
NCT01363440

Study of Nesvacumab (REGN910/ SAR307746)

Phase 1
Completed
Conditions
Solid Tumors
Interventions
Drug: nesvacumab (REGN910/ SAR307746)
First Posted Date
2011-01-07
Last Posted Date
2015-06-16
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
53
Registration Number
NCT01271972

Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia

Phase 2
Completed
Conditions
Hypercholesterolemia
Interventions
Drug: Alirocumab
Drug: Placebo
First Posted Date
2010-12-24
Last Posted Date
2015-09-22
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
77
Registration Number
NCT01266876

Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis

Phase 1
Completed
Conditions
Dermatitis
Interventions
Biological: REGN668
First Posted Date
2010-12-14
Last Posted Date
2012-10-04
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
30
Registration Number
NCT01259323

A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee

Phase 2
Withdrawn
Conditions
Osteoarthritis
Interventions
Biological: REGN475
Other: Placebo
First Posted Date
2010-11-11
Last Posted Date
2015-03-18
Lead Sponsor
Regeneron Pharmaceuticals
Registration Number
NCT01239017

Safety and Tolerability Study of REGN846 (SAR302352) in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Biological: REGN846
First Posted Date
2010-09-27
Last Posted Date
2012-06-01
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
40
Registration Number
NCT01209793
Locations
🇦🇺

Nucleus Network, Melbourne, Australia

Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Biological: REGN728
First Posted Date
2010-09-09
Last Posted Date
2012-11-12
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
48
Registration Number
NCT01197391
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy